Yes, treat this patient for H. pylori infection.
A focal positive H. pylori immunostain represents active infection and warrants eradication therapy, regardless of negative H&E staining, as immunohistochemistry is the most accurate detection method for H. pylori. 1
Rationale for Treatment
The immunohistochemical staining is specifically designed to detect H. pylori with superior accuracy compared to routine H&E staining 1. When immunostain is positive—even if focal—this confirms active infection requiring treatment. The mild chronic gastritis pattern is entirely consistent with H. pylori infection, and the organism's presence explains the gastric inflammation.
Why Immunostain Trumps H&E
Immunohistochemistry using H. pylori-specific antibodies is the most accurate histologic method for detecting the organism 1. H&E staining can miss organisms when bacterial load is low or patchy, which appears to be your patient's situation. The pathology report's phrasing "focal positive on immunostain" indicates genuine infection, not artifact.
Treatment Approach
First-line therapy should be bismuth quadruple therapy (bismuth + PPI + metronidazole + tetracycline) for 14 days 2. This regimen is specifically recommended because it:
- Achieves >90% eradication rates even with metronidazole-resistant strains
- Avoids clarithromycin (which has declining efficacy due to resistance)
- Works regardless of prior antibiotic exposure
Alternative if bismuth unavailable: Concomitant 4-drug therapy with PPI + clarithromycin + amoxicillin + metronidazole 2.
PPI Selection Matters
Use high-potency PPIs: rabeprazole 20-40 mg twice daily or esomeprazole 20-40 mg twice daily 1. Avoid pantoprazole as it has significantly lower potency. The PPI dose directly impacts amoxicillin-containing regimen success rates.
Addressing the Complete Clinical Picture
The patient's symptoms (heartburn, diarrhea, lower abdominal pain) span both upper and lower GI tracts:
- Heartburn and gastritis: Directly attributable to H. pylori infection
- Diarrhea and lower abdominal pain: The colonic findings without definitive lymphocytic colitis suggest possible functional overlap, but treating H. pylori may improve overall symptoms
Eradicating H. pylori cures gastritis and prevents progression to peptic ulcer disease and gastric cancer—both significant morbidity/mortality concerns 2. The infection is responsible for >80% of gastric cancers globally 2.
Post-Treatment Confirmation Required
Confirm eradication 4-6 weeks after completing therapy using urea breath test or stool antigen test 1, 3. Do not use serology, as it remains positive long after eradication (creates a "serologic scar") 1.
Critical Timing for Testing
Stop PPIs for at least 2 weeks before confirmatory testing to avoid false negatives 1. Antibiotics and bismuth also reduce bacterial load temporarily. However, if the test is positive despite these medications, trust the result—these factors don't cause false positives 1.
Common Pitfalls to Avoid
- Don't dismiss focal positive immunostain: This is real infection, not background noise
- Don't use clarithromycin-based triple therapy empirically: Resistance rates have made this obsolete as first-line 2
- Don't rely on symptoms alone: H. pylori gastritis requires eradication regardless of symptom severity to prevent long-term complications
- Don't use serology for post-treatment confirmation: Only breath test or stool antigen are appropriate 1
The goal is >90% cure rate on first attempt to avoid retreatment, reduce antibiotic resistance, and minimize cost and patient anxiety 2, 1.